The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy

Journal of Surgical Oncology

Volumn 104, Issue 6, 2011, Pages 661-666

  Lin, Jen Kou ^a   Lin, An Jen ^a   Lin, Chun Chi ^a   Lan, Yuan Tzu ^a   Yang, Shung Haur ^a   Li, Anna Fen Yau ^a   Chang, Shih Ching ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

BRAF; cetuximab; colorectal cancer; EGFR; KRAS; PTEN

Indexed keywords

B RAF KINASE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL EVALUATION; COLORECTAL CANCER; FEMALE; GENE DOSAGE; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MALE; METASTASIS; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEQUENCE ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS B-RAF; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 80053586454     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21993     Document Type: Article

References (37)

1. Cancer registry annual report, Taiwan, R.O.C. The Department of Health, the executive Yuan, R.O.C. December 2006.
2. de Gramont A, Figer A, Seymour M, et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947. (Pubitemid 30644117)
3. Douillard JY, Cunningham D, Roth AD, et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000; 355: 1041-1047. (Pubitemid 30162806)
4. Resnick MB, Routhier J, Konkin T, et al.: Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: A tissue microarray study. Clin Cancer Res 2004; 10: 3069-3075. (Pubitemid 38619685)
5. Galizia G, Lieto E, Ferraraccio F, et al.: Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. Ann Surg Oncol 2006; 13: 823-835. (Pubitemid 43727367)
6. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al.: Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357: 2040-2048. (Pubitemid 350106711)
7. Chung KY, Shia J, Kemeny NE, et al.: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23: 1803-1810. (Pubitemid 46211358)
8. Saridaki Z, Tzardi M, Papadaki C, et al.: Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in >/=2 line cetuximab-based therapy of colorectal cancer patients. PLoS One 2011; 6: e15980.
9. Moroni M, Veronese S, Benvenuti S, et al.: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: A cohort study. Lancet Oncol 2005; 6: 279-286. (Pubitemid 40590264)
10. Sartore-Bianchi A, Moroni M, Veronese S, et al.: Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007; 25: 3238-3245. (Pubitemid 47325607)
11. Cappuzzo F, Finocchiaro G, Rossi E, et al.: EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol 2008; 19: 717-723. (Pubitemid 351461042)
12. Lievre A, Bachet JB, Boige V, et al.: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26: 374-379. (Pubitemid 351171687)
13. Amado RG, Wolf M, Peeters M, et al.: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634.
14. De Roock W, Piessevaux H, De Schutter J, et al.: KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008; 19: 508-515. (Pubitemid 351325672)
15. Karapetis CS, Khambata-Ford S, Jonker DJ, et al.: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765.
16. Lievre A, Bachet JB, Le Corre D, et al.: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992-3995.
17. Di Nicolantonio F, Martini M, Molinari F, et al.: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26: 5705-5712.
18. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al.: Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007; 67: 2643-2648. (Pubitemid 46548951)
19. Perrone F, Lampis A, Orsenigo M, et al.: PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 2009; 20: 84-90.
20. Mendelsohn J, Baselga J,: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21: 2787-2799. (Pubitemid 46606324)
21. Kato S, Iida S, Higuchi T, et al.: PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. Int J Cancer 2007; 121: 1771-1778. (Pubitemid 47417296)
22. Bardelli A, Siena S,: Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010; 28: 1254-1261.
23. Eisenhauer EA, Therasse P, Bogaerts J, et al.: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
24. Santini D, Spoto C, Loupakis F, et al.: High concordance of BRAF status between primary colorectal tumours and related metastatic sites: Implications for clinical practice. Ann Oncol 2010; 21: 1565.
25. Artale S, Sartore-Bianchi A, Veronese SM, et al.: Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 2008; 26: 4217-4219.
26. Samuels Y, Wang Z, Bardelli A, et al.: High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554. (Pubitemid 38541907)
27. Benvenuti S, Frattini M, Arena S, et al.: PIK3CA cancer mutations display gender and tissue specificity patterns. Hum Mutat 2008; 29: 284-288. (Pubitemid 351240601)
28. Dicuonzo G, Angeletti S, Garcia-Foncillas J, et al.: Colorectal carcinomas and PTEN/MMAC1 gene mutations. Clin Cancer Res 2001; 7: 4049-4053. (Pubitemid 34044626)
29. Italiano A, Follana P, Caroli FX, et al.: Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number. Ann Surg Oncol 2008; 15: 649-654.
30. Khambata-Ford S, Garrett CR, Meropol NJ, et al.: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25: 3230-3237. (Pubitemid 47325606)
31. Lenz HJ, Van Cutsem E, Khambata-Ford S, et al.: Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006; 24: 4914-4921. (Pubitemid 46630920)
32. Vallbohmer D, Zhang W, Gordon M, et al.: Molecular determinants of cetuximab efficacy. J Clin Oncol 2005; 23: 3536-3544.
33. Gandhi J, Zhang J, Xie Y, et al.: Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One 2009; 4: e4576.
34. Rosenberg C, Schut TB, Mostert MC, et al.: Comparative genomic hybridization in hypotriploid/hyperdiploid tumors. Cytometry 1997; 29: 113-121. (Pubitemid 27444660)
35. Saltz LB, Meropol NJ, Loehrer PJ, et al.: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-1208. (Pubitemid 41079832)
36. Cunningham D, Humblet Y, Siena S, et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345. (Pubitemid 38944402)
37. Atkins D, Reiffen KA, Tegtmeier CL, et al.: Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: Variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 2004; 52: 893-901. (Pubitemid 38857154)